Late immune tolerance induction in haemophilia A patients-Reference-Cited by-同舟云学术

Late immune tolerance induction in haemophilia A patients

Published:2013-01-07 Issue:3 Volume:19 Page:445-448
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Meeks S. L.¹,Chapman R. L.¹,Kempton C.,Dunn A. L.¹

Affiliation:

1. Aflac Cancer Center and Blood Disorders Service; Children's Healthcare of Atlanta; Emory University; Atlanta; GA,; USA

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hae.12077/fullpdf

Reference26 articles.

1. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group;Bray;Blood,1994

2. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products;Kreuz;Semin Thromb Hemost,2002

3. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group;Lusher;N Engl J Med,1993

4. ReFacto Phase 3 Study G. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A.[see comment];Lusher;Haemophilia,2003

5. The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients;Astermark;Haemophilia,2001

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oral tolerance to prevent anti-drug antibody formation in protein replacement therapies;Cellular Immunology;2022-12

2. CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications;Biomedicines;2022-01-26

3. CD4+ T cells engineered with FVIII-CAR and murine Foxp3 suppress anti-factor VIII immune responses in hemophilia a mice;Cellular Immunology;2020-12

4. Modelling future usage and cost of factor and emicizumab to treat haemophilia A for the US Western States Region IX haemophilia treatment centres;Haemophilia;2020-10-04

5. A Treg-Selective IL-2 Mutein Prevents the Formation of Factor VIII Inhibitors in Hemophilia Mice Treated With Factor VIII Gene Therapy;Frontiers in Immunology;2020-04-28